当前肺动脉高压管理时代的门肺高压长期结局
中位治疗4.5个月后功能分级、6分钟步行距离和肺血管阻力显著改善;1、3、5年总生存率分别为84%、69%、51%,生存与肝病严重程度密切相关,接受肝移植者长期结局最佳。
要点
- 门肺高压患者1、3、5年生存率分别为84%、69%、51%。
- 基线6分钟步行距离、性别、年龄和MELD评分或Child-Pugh分期为独立预后因素。
- 接受肝移植的患者长期生存最佳(1、3、5年分别为92%、83%、81%)。
核心结论
- 门肺高压患者生存与肝病严重程度强烈相关,接受肝移植者长期结局最佳。
主要发现
- 74%(474例)起始单药治疗,其中磷酸二酯酶-5抑制剂336例、内皮素受体拮抗剂128例;15%(95例)起始双联口服治疗,1%(5例)起始三联治疗。
- 中位治疗4.5个月后,功能分级(p<0.001)、6分钟步行距离(p<0.0001)和肺血管阻力(p<0.0001)均显著改善。
- 1、3、5年总生存率分别为84%、69%、51%;基线6分钟步行距离、性别、年龄和MELD评分或Child-Pugh分期为独立预后因素。
- 接受肝移植亚组1、3、5年生存率分别为92%、83%、81%,显著优于未移植者。
临床怎么用
- 对门肺高压患者应评估肝病严重程度(MELD评分或Child-Pugh分期),因其与生存强烈相关。
- 肺动脉高压靶向治疗可改善功能分级、运动能力和肺血管阻力,为肝移植创造条件。
- 严重肺动脉高压是肝移植禁忌证,但靶向治疗有效者可安全接受移植并获良好长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Long-term outcomes in portopulmonary hypertension (PoPH) are poorly studied in the current era of pulmonary hypertension management. We analysed the effect of pulmonary arterial hypertension (PAH)-targeted therapies, survival and predictors of death in a large contemporary cohort of patients with PoPH. METHODS: Data from patients with PoPH consecutively enrolled in the French Pulmonary Hypertension Registry between 2007 and 2017 were collected. The effect of initial treatment strategies on functional class, exercise capacity and cardiopulmonary haemodynamics were analysed. Survival and its association with PAH- and hepatic-related characteristics were also examined. RESULTS: Six hundred and thirty-seven patients (mean age 55 ± 10 years; 58% male) were included. Fifty-seven percent had mild cirrhosis, i.e. Child-Pugh stage A. The median model for end-stage liver disease (MELD) score was 11 (IQR 9-15). Most patients (n = 474; 74%) were initiated on monotherapy, either with a phosphodiesterase-5 inhibitor (n = 336) or with an endothelin-receptor antagonist (n = 128); 95 (15%) were initiated on double oral combination therapy and 5 (1%) on triple therapy. After a median treatment time of 4.5 months, there were significant improvements in functional class (p <0.001), 6-minute walk distance (6MWD) (p <0.0001) and pulmonary vascular resistance (p <0.0001). Overall survival rates were 84%, 69% and 51% at 1, 3 and 5 years, respectively. Baseline 6MWD, sex, age and MELD score or Child-Pugh stage were identified as independent prognostic factors. Survival from PoPH diagnosis was significantly better in the subgroup of patients who underwent liver transplantation (92%, 83% and 81% at 1, 3 and 5 years, respectively). CONCLUSION: Survival of patients with PoPH is strongly associated with the severity of liver disease. Patients who underwent liver transplantation had the best long-term outcomes. LAY SUMMARY: Portopulmonary hypertension is defined by the presence of pulmonary arterial hypertension in the context of chronic liver disease and is characterized by progressive shortness of breath and exercise limitation. The presence of severe pulmonary arterial hypertension in liver transplant candidates represents a contraindication for such a surgery; however, treatments targeting pulmonary arterial hypertension are efficacious, allowing for safe transplantation and conferring good survival outcomes in those who undergo liver transplantation.
引用
- Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020. PMID: 32145258. doi:10.1016/j.jhep.2020.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。